
    
      Principal objective

      To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir
      (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination with a
      fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-naïve subjects with CD4 counts below
      200 µL.

      Secondary objectives

        -  Proportion of subjets with virologic efficacy at week 24

        -  Proportion of subjects with confirmed virologic failure at week 24 or later

        -  Proportion of patients with virologic mutations

        -  Evaluate the virologic effect in seminal fluid

        -  To evaluate immunological response over time up to week 48

        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at
           week 4, 24, and 48

        -  Correlate the pharmacokinetic properties of the drugs with virologic outcome in plasma
           and semen at week 4 and 48

        -  Correlate the free fraction (not bound to protein) of atazanavir and darunavir in plasma
           and semen to virologic outcome

        -  Evaluate the relationship of bilirubinemia with atazanavir

        -  Change from baseline in fasting lipids, fasting glucose and insulin over time in the 2
           arms

        -  Compare adherence patient satisfaction and sexual behaviour between the regimens

      Methodology

      This is a 48 week, multicentre, prospective, open label, phase IV, randomized. non
      comparative, study.

      Inclusion criteria

        -  Male or female, aged > 18 years of age.

        -  HIV-1 infection determined by a positive ELISA and confirmed by Western blot

        -  Plasma HIV-RNA > 1 000 c/mL

        -  CD4+T cell count < =200 cells/mm3 at the time of screening, or < =250 cells/mm3 if the
           CD4 count was <200 cells/mm3 12 weeks before screening.

        -  Women of childbearing potential must agree to use an effective method of barrier
           contraception or have documented sterility.

        -  Subjects must have medical insurance throught the Securite Sociale

        -  Ability to understand and provide written informed consent.

      Non-inclusion criteria

        -  Acute opportunistic infection within the past two weeks

        -  HIV-2 infection

        -  pregnant woman

        -  Any subject with drug resistance mutations at screening

        -  Any subject with a grade 3 or greater clinical or laboratory adverse event at screening

        -  Any subject who has received antiretoviral therapy except for prevention of mother to
           child transmission and patients who has received post exposure prophylaxis for a a month
           or less

        -  calculated creatinine clearance < 60/mL as estimated by the Cockcroft- Gault equation

        -  Patients in the opinion of the investigator that are unlikley to be able to follow study
           instructions

        -  Any subject unable to take antiretroviral medication for whatever reason

        -  Any subject taking a treatment or medication that is contraindicated when
           co-administered with any arm or drug in the treatment.

      Treatment:

        -  Group 1 : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if TDF/FTc contre-indicated

        -  atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg by day, 3 pills once a day,
           during 48 weeks during a meal

        -  Group 2 : DRV+ TDF/FTC (or ABC/3TC if TDF/FTc contre-indicated)

        -  darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg by day, 4 pills once a day,
           during 48 weeks during a meal

      Primary Endpoints :

        -  Proportion of patients with HIV-1 plasma viral load below 50 copies/mL at week 48 while
           receiving their initial regimen

        -  Proportion of patients experiencing grade 2-4 adverse clinical and laboratory events
           including hematology, chemistry, lipids (total cholesterol, HDL cholesterol, LDL
           cholesterol, triglycerides), glucose and insulin by week 48.

      Secondary endpoints:

        -  Proportion of patients with plasma HIV RNA below 50 cp/mL at week 24

        -  Proportion of patients with HIV RNA> 50 cp/mL at week 24 or later confirmed by a second
           HIV RNA at least 14 days after the first test

        -  Development of resistance mutations in subjects who have virologic failure testing at 24
           weeks or later tested by a genotypic resistance test

        -  Evaluate the virologic effect in seminal fluid at baseline, W4 and W48 by change in HIV
           RNA concentrations in semen over time

        -  To evaluate immunological response over time up to week 48 in the 2 arms by CD4 cell
           count ( W-4, W2,W4, W12, W36 and W48), differenciation and activation in T CD4 ( W2,W4,
           W12, W24 and W48); Change in lymphocyte subset reconsistution at week 48 compared to
           baseline. ; Change in immunolgic markers of inflammations at weeks 2, 4, 12, 24, 48

        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at
           week 4, 24, and 48 through residual concentrations ( C min) of antiretroviral drugs at
           W4, W24, and W48

        -  Atazanavir and darunavir (plasma and seminal) drug concentrations and coorelation with
           adverse clinical and laboratory events.

        -  Evaluate the relationship of bilirubinemia with atazanavir pharmacokinetics (Cmin)

        -  Evolution of lipid, glucose and insulin parameters from baseline to weeks 24 and 48

        -  Adherence to regimen, patient satisfaction and sexual behaviour between the regimens at
           W2,W24 and W48 mesured by ( mettre ref)

        -  Evolution of anthropomorphic measurements from baseline to weeks 24, 48.

      Substudies Brief description (2 lines maximum) and person in charge of the substudy

        -  Immunologic substudy ( Pr Brigitte Autran) : Change in immunolgic markers of
           inflammations at weeks 2, 4, 12, 24, 48 and change in lymphocyte subset reconsistution
           at week 48 compared to baseline.

        -  Pharmacologic substudy ( Dr Gilles Peytavin) : To assess plasma and seminal
           pharmacokinetics of the drugs in the treatment regimen at week 4, 24, and 48 through
           residual concentrations ( C min) of antiretroviral drugs at W4, W24, and W48

        -  Virologic substudy ( Dr Anne Geneviève Marcelin) : Evaluate the virologic effect in
           seminal fluid at baseline, W4 and W48

        -  Behaviour substudy ( Dr France Lert) : Compare adherence patient satisfaction and sexual
           behaviour between the regimens at W2,W24 and W48

      Estimated enrolment: 120 subjects (60 per group) randomly assigned 1:1
    
  